Profile data is unavailable for this security.
About the company
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. The Company is leveraging its switch-control kinase inhibitor platform in kinase biology to develop a portfolio of medicines. The Company's QINLOCK, is a switch-control kinase inhibitor, engineered using its drug discovery platform and developed for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition to QINLOCK, it has developed a robust pipeline of drug candidates using its switch-control kinase inhibitor platform, including vimseltinib and DCC-3116. Vimseltinib is an investigational, orally administered, potent, and highly-selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) kinase for the potential treatment of tenosynovial giant cell tumor (TGCT). DCC-3116 is a Phase 1/2 inhibitor of ULK kinases being developed to inhibit autophagy.
- Revenue in USD (TTM)163.36m
- Net income in USD-194.94m
- Incorporated2017
- Employees355.00
- LocationDeciphera Pharmaceuticals Inc200 Smith StWALTHAM 02451-0099United StatesUSA
- Phone+1 (781) 209-6400
- Fax+1 (302) 655-5049
- Websitehttps://www.deciphera.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SAGE Therapeutics Inc | 86.46m | -541.49m | 1.14bn | 487.00 | -- | 1.43 | -- | 13.24 | -9.05 | -9.05 | 1.44 | 13.32 | 0.0772 | -- | 1.79 | 177,527.70 | -48.37 | -21.88 | -52.66 | -23.30 | 97.50 | 99.63 | -626.32 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
Liquidia Corp | 17.49m | -78.50m | 1.15bn | 136.00 | -- | 21.87 | -- | 65.52 | -1.21 | -1.21 | 0.2691 | 0.6891 | 0.1413 | -- | 3.85 | 128,588.20 | -63.43 | -55.02 | -71.31 | -62.69 | 83.49 | 82.18 | -448.89 | -474.59 | -- | -26.14 | 0.4942 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.18bn | 264.00 | -- | 4.72 | -- | 6.34 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.19bn | 20.00 | -- | 12.87 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
Scholar Rock Holding Corp | 0.00 | -165.79m | 1.20bn | 150.00 | -- | 5.21 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Pharvaris NV | 0.00 | -116.19m | 1.22bn | 65.00 | -- | 5.81 | -- | -- | -3.18 | -3.18 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -57.65 | -- | -63.41 | -- | -- | -- | -- | -- | -- | -6.96 | 0.0019 | -- | -- | -- | -78.64 | -- | -- | -- |
Deciphera Pharmaceuticals Inc | 163.36m | -194.94m | 1.23bn | 355.00 | -- | 3.48 | -- | 7.51 | -2.29 | -2.29 | 1.92 | 4.36 | 0.3522 | 0.1787 | 6.01 | 460,157.80 | -42.03 | -44.54 | -52.63 | -52.24 | 97.72 | -- | -119.34 | -245.88 | 3.59 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
MannKind Corp | 198.96m | -11.94m | 1.25bn | 414.00 | -- | -- | -- | 6.29 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.26bn | 58.00 | 24.52 | 1.79 | 13.97 | 9.61 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
Tarsus Pharmaceuticals Inc | 17.45m | -135.89m | 1.30bn | 244.00 | -- | 6.00 | -- | 74.29 | -4.58 | -4.58 | 0.5939 | 5.76 | 0.0707 | -- | 1.64 | 71,504.10 | -55.09 | -31.56 | -61.63 | -33.82 | 90.87 | -- | -778.89 | -242.59 | 6.85 | -- | 0.1315 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.31bn | 197.00 | 46.37 | 6.67 | 6.62 | 2.31 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
AbCellera Biologics Inc | 38.03m | -146.40m | 1.31bn | 586.00 | -- | 1.13 | -- | 34.57 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Gyre Therapeutics Inc | 0.00 | -44.24m | 1.34bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.35bn | 267.00 | -- | -- | -- | 3.05 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Dec 2023 | 5.20m | 6.44% |
Redmile Group LLCas of 31 Dec 2023 | 4.80m | 5.94% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 4.79m | 5.92% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 4.31m | 5.33% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.47m | 3.06% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.10m | 2.59% |
Polar Capital LLPas of 31 Dec 2023 | 1.85m | 2.29% |
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 2023 | 1.82m | 2.25% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 1.56m | 1.93% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.22m | 1.51% |